Advertisement
Canada markets close in 3 hours 28 minutes

  • S&P/TSX

    21,767.62
    +59.18 (+0.27%)
     

  • S&P 500

    4,968.10
    -43.02 (-0.86%)
     

  • DOW

    37,837.78
    +62.40 (+0.17%)
     

  • CAD/USD

    0.7268
    +0.0004 (+0.06%)
     

  • CRUDE OIL

    83.00
    +0.27 (+0.33%)
     

  • Bitcoin CAD

    87,767.02
    -90.14 (-0.10%)
     

  • CMC Crypto 200

    1,378.46
    +65.84 (+5.01%)
     

  • GOLD FUTURES

    2,405.10
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    1,941.45
    -1.51 (-0.08%)
     

  • 10-Yr Bond

    4.6100
    -0.0370 (-0.80%)
     

  • NASDAQ

    15,320.95
    -280.55 (-1.80%)
     

  • VOLATILITY

    18.86
    +0.86 (+4.78%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Apple pulls WhatsApp and Threads from China App Store

Why Puma Biotechnology's Shares Jumped 20% on Monday

Jim Halley, The Motley Fool
·2 min read
Why Puma Biotechnology's Shares Jumped 20% on Monday

The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.

Continue reading